CRIS - Curis, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.0900
-0.0400 (-3.54%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.1300
Open1.1300
Bid0.91 x 1300
Ask1.11 x 1300
Day's Range1.0700 - 1.1300
52 Week Range0.6000 - 5.2000
Volume82,778
Avg. Volume385,743
Market Cap36.093M
Beta (3Y Monthly)1.55
PE Ratio (TTM)N/A
EPS (TTM)-1.05
Earnings DateMar 6, 2019 - Mar 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.00
Trade prices are not sourced from all markets
  • PR Newswire19 days ago

    Curis, Inc. to Present at the 2019 BIO CEO & Investor Conference

    LEXINGTON, Mass. , Feb. 4, 2019 /PRNewswire/ --   Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced ...

  • Has Curis (CRIS) Outpaced Other Medical Stocks This Year?
    Zacks25 days ago

    Has Curis (CRIS) Outpaced Other Medical Stocks This Year?

    Is (CRIS) Outperforming Other Medical Stocks This Year?

  • PR Newswirelast month

    First Mesothelioma Patient Dosed in CA-170 Study

    LEXINGTON, Mass., Jan. 24, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the first mesothelioma patient has been enrolled and dosed in the Phase I study of CA-170. CA-170 is an orally available, dual inhibitor of VISTA and PDL1, which the company believes could provide benefit in tumors with high levels of VISTA expression. The company had previously announced its expectation to begin enrollment of mesothelioma patients in a dedicated cohort within the existing Phase 1 study.

  • First Eagle Investment Sells Stake in Curis Inc. at Steep Loss
    GuruFocus.comlast month

    First Eagle Investment Sells Stake in Curis Inc. at Steep Loss

    First Eagle Investment (Trades, Portfolio) Management axed 90.99% of its stake in Curis Inc. (CRIS) on Dec. 31 as the stock hovered near all-time low prices, the New York-based firm disclosed Wednesday. Warning! GuruFocus has detected 3 Warning Signs with CRIS.

  • Is Curis (CRIS) Outperforming Other Medical Stocks This Year?
    Zackslast month

    Is Curis (CRIS) Outperforming Other Medical Stocks This Year?

    Is (CRIS) Outperforming Other Medical Stocks This Year?

  • Top 3 Healthcare Penny Stocks for 2018
    Investopedialast month

    Top 3 Healthcare Penny Stocks for 2018

    These three healthcare penny stocks are poised for positive performance in the final quarter of 2018.

  • PR Newswire2 months ago

    Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    LEXINGTON, Mass., Jan. 4, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on January 2, 2019, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase 30,000 shares of Curis common stock to a new employee, with a grant date of January 2, 2019 (the "Q1 2019 Inducement Grant").

  • GlobeNewswire3 months ago

    Analysis: Positioning to Benefit within Dicerna Pharmaceuticals, Sun Life Financial, Autodesk, Eagle Pharmaceuticals, Curis, and Accenture — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Nov. 30, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • PR Newswire3 months ago

    Curis to Present at the 60th Annual Meeting of the American Society of Hematology

    LEXINGTON, Mass. , Nov. 20, 2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, ...

  • PR Newswire4 months ago

    Curis to Present at 33rd Society for Immunotherapy of Cancer Annual Meeting and Cowen IO NEXT Summit

    LEXINGTON, Mass. , Nov. 7, 2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, ...

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of CRIS earnings conference call or presentation 1-Nov-18 12:30pm GMT

    Q3 2018 Curis Inc Earnings Call

  • Curis (CRIS) Reports Q3 Loss, Tops Revenue Estimates
    Zacks4 months ago

    Curis (CRIS) Reports Q3 Loss, Tops Revenue Estimates

    Curis (CRIS) delivered earnings and revenue surprises of 29.03% and 19.62%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press4 months ago

    Curis: 3Q Earnings Snapshot

    On a per-share basis, the Lexington, Massachusetts-based company said it had a loss of 22 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...

  • PR Newswire4 months ago

    Curis Reports Third Quarter 2018 Financial Results

    LEXINGTON, Mass., Nov. 1, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2018. "Following Curis's recent leadership change, we are increasing our focus on the clinical execution of our three first-in-class therapeutics that have the potential to be significant and innovative cancer treatments. "To achieve this goal, we are re-allocating resources to prioritize clinical operations and have implemented a reduction in headcount and expenditure on pre-clinical science, pipeline expansion, and general and administrative expenses.

  • PR Newswire4 months ago

    Curis to Release Third Quarter Financial Results and Hold Conference Call on November 1, 2018

    LEXINGTON, Mass., Oct. 23, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced that the Company will release its third quarter 2018 financial results on Thursday, November 1, 2018, before the U.S. financial markets open. The Company's management will also host a conference call on the same day at 8:30 a.m. ET. Curis is a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, including fimepinostat, which is being investigated in clinical studies in patients with DLBCL and solid tumors.

  • Curis (CRIS) Shares March Higher, Can It Continue?
    Zacks4 months ago

    Curis (CRIS) Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in Curis, Inc. (CRIS).

  • Simply Wall St.5 months ago

    Who Are The Top Investors In Curis Inc (NASDAQ:CRIS)?

    Every investor in Curis Inc (NASDAQ:CRIS) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders owning Read More...

  • PR Newswire5 months ago

    Curis to Present at the Cantor Fitzgerald Global Healthcare Conference

    James Dentzer, the Company's new President & Chief Executive Officer, will provide a brief overview of the Company's pipeline of drug candidates and business strategy. A live webcast of the presentation will be available by visiting the investor section of Curis' website http://investors.curis.com/events-and-presentations.

  • PR Newswire5 months ago

    Curis Announces Leadership Change

    LEXINGTON, Mass., Sept. 24, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced a change in leadership with the appointment of James E. Dentzer as President and Chief Executive Officer effective immediately. In addition, Mr. Dentzer will become a member of the Curis Board of Directors. Mr. Dentzer, who joined Curis in 2016, was promoted earlier this year to Chief Operating Officer to manage all functions outside of research and development, including business development, manufacturing, quality, human resources, finance, legal, IT, and investor and public relations.

  • PR Newswire6 months ago

    Curis to Present at the Baird 2018 Global Healthcare Conference

    LEXINGTON, Mass., Aug. 28, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that the Company will present at the Baird 2018 Global Healthcare Conference on Wednesday, September 5 at 2:35-3:05 PM in Session III - Empire Ballroom B, Mezzanine Level of the InterContinental New York Barclay in New York. The presentation will be held using a fireside-chat format in which Ali Fattaey, Ph.D. President and Chief Executive Officer, will provide a brief overview of the Company's pipeline of drug candidates and business strategy, after which an equity analyst will moderate a question and answer session. A live webcast of the presentation will be available by visiting the investors section of Curis' website http://investors.curis.com/events-and-presentations.

  • Thomson Reuters StreetEvents7 months ago

    Edited Transcript of CRIS earnings conference call or presentation 2-Aug-18 12:30pm GMT

    Q2 2018 Curis Inc Earnings Call